title: [Prolactin secretion disturbances in schizophrenic patients treated with 2nd generation antipsychotics--risperidone and olanzapine].
abstract: Hyperprolactinemia is an elevation ofprolactin level above the norm in two separate samples. Its prevalence is 0.4%. Hyperprolactinemia could be a side effect oftreatment of schizophrenia with conventional and some of the second generation antipsychotics.
  
  
  OBJECTIVE
  To compare the prevalence of hyperprolactinemia and its clinical symptoms in three groups: (1) patients with schizophrenia treated with risperidone, (2) those treated with olanzapine and (3) the control group.
  
  
  METHODS
  Participants in the study were 60 schizophrenic patients: 26 treated with risperidone, 34 with olanzapine and 38 healthy, non-medicated volunteers. In all subjects a fasting morning blood sample was obtained and analyzed for serum prolactin levels.
  
  
  RESULTS
  Investigators did not establish any statistically significant difference in the prevalence of hyperprolactinemia diagnosed with laboratory tests in patients treated with different atypical neuroleptics. Hyperprolactinemia was established in 92.3% patients treated with risperidone and in 76.5% patients treated with olanzapine and in 2.6% subjects of the control group. Clinical symptoms of hyperprolactinemia were established only in a part of the subjects with hiperprolactinemia diagnosed with laboratory tests.
authors.affiliation: Centralny Szpital Kliniczny UM w Lodzi.
authors.forename: Anna
authors.initials: A
authors.lastname: Wyszogrodzka-Kucharska
authors.forename: Jolanta
authors.initials: J
authors.lastname: Kunert-Radek
authors.forename: Jolanta
authors.initials: J
authors.lastname: Rabe-Jabłońska
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000494:pharmacology / Q000627:therapeutic use; D004298:Dopamine; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000175:diagnosis / Q000453:epidemiology / Q000378:metabolism; D008297:Male; D008787:Metoclopramide; D008875:Middle Aged; D000077152:Olanzapine; D015995:Prevalence; D011388:Prolactin / Q000378:metabolism*; D018967:Risperidone / Q000494:pharmacology* / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy* / Q000453:epidemiology / Q000378:metabolism*
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D011388:Prolactin; D008787:Metoclopramide; D018967:Risperidone; D000077152:Olanzapine; D004298:Dopamine